This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).

NCT04334512

Conditions

1. COVID-19
2. Corona Virus Infection
3. Coronavirus-19
4. Sars-CoV2

Interventions

1. Drug: Hydroxychloroquine
2. Drug: Azithromycin
3. Dietary Supplement: Vitamin C
4. Dietary Supplement: Vitamin D
5. Dietary Supplement: Zinc

MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19

NCT04335084

Conditions

1. COVID-19
2. Coronavirus Infection
3. Sars-CoV2
4. Corona Vi
5. Corona Virus Infection
6. COVID
7. Coronavirus
8. Coronavirus-19
9. Coronavirus 19

Interventions

1. Drug: Hydroxychloroquine
2. Dietary Supplement: Vitamin C
3. Dietary Supplement: Vitamin D
4. Dietary Supplement: Zinc

MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

A multicenter randomized clinical trial aiming to assess the efficacy of hydroxychloroquine associated to Zinc compared to hydroxychloroquine, in the prevention of Military Health Professionals Exposed to SARS CoV2 in Tunisia

NCT04377646

Conditions

1. Sars-CoV2
2. COVID19

Interventions

1. Drug: Hydroxychloroquine
2. Drug: Hydroxychloroquine (placebo)
3. Drug: Zinc
4. Drug: Zinc (Placebo)

MeSH:Infection

In December 2019, a novel coronavirus, now called COVID-19, emerged as a global health threat from Wuhan, China. Within weeks, the contagious virus spread within and between communities, causing a lower respiratory tract infection dominated by symptoms of fever, cough and sore throat. The incubation period was estimated at between 5 to 7 days, but could last as long as 14 days. Although COVID-19 causes a mostly mild and self-limiting disease, respiratory involvement has been reported in about 5% of the population, requiring supplemental oxygen and even ventilatory support to relieve hypoxia. Alveolar damage, fibrosis and consolidation have been reported in radiologic and post-mortem studies. Existing data suggest a mortality rate of COVID-19 is approximately 1-2%, higher among individuals with pre-existing comorbidities and in healthcare systems with suboptimal access to ventilatory support. Given its high transmissibility, COVID-19 has quickly spread across the globe within a short interval. By 27 April 2020, over 3 million people around the world have been diagnosed with COVID-19, and more 200,000 have succumbed to the disease. As a proportion of patients manifest mild or no symptoms, these numbers are likely an underestimate of the actual number of patients with COVID-19. More disconcertingly, patients are known to shed viruses despite mild or no symptoms, making it essential that a collective approach against COVID-19 incorporate active pharmacological treatment to prevent or mitigate virus pathogenesis prior to its potential evolution to cause respiratory distress. To date, clinical trials have focused on the treatment of hospitalised patients diagnosed with COVID-19; only few have examined the clinical benefits of pharmacological agents despite few compelling in vitro data. The relatively high transmission of COVID-19 in a closed dormitory environment of migrant workers in Singapore presents a real-life scenario where a prophylaxis treatment could reduce the impact of the disease. In Singapore, there are well grounded concerns an excess in cases could pose the possibility of strain in healthcare system and mentally drain her workers. The availability of an effective prophylaxis treatment is highly desirable to potentially reduce this burden. Data from the current study could also have implications on how future outbreaks in high-density areas should be managed, especially when residents are subjected to quarantine and isolation.

NCT04446104

Conditions

1. Covid-19

Interventions

1. Drug: Hydroxychloroquine Sulfate Tablets
2. Drug: Ivermectin 3mg Tab
3. Drug: Zinc
4. Drug: Povidone-Iodine
5. Dietary Supplement: Vitamin C

There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. The drugs we are chosen are used as clinical trials for antiviral and there is no proven guide for specificity and effectiveness against the virus so the results are different Now the clinical trials and research authorities are work speedily to target the most proven treatment for the virus so anything is infantile until now. the covid-19 with time be more explained by scientists it is steroid response disease and cause thromosis and cytokine storm , the aim of the study to inhibit viral replication and decrease the severity of the disease as antiviral and anticytokine storm , antithrombosis Zinc is a mineral element needed to regulate adaptive immune cells' functions. Higher level of intracellular zinc showed to increase intracellular pH; which affect on RNA-dependent RNA polymerase and decrease replication mechanism of RNA viruses. Therefore, drugs that described as zinc ionophores could be used with zinc supplement to act as antiviral against many RNA viruses including SARS-CoV-2 Quercetin is natural compound act as zinc ionophore to cause zinc influx intracellular. Quercetin is a safe natural anti-oxidant and anti-inflammatory polyphenolic compound that found in various natural sources include onion, red grapes, honey and citrus fruits. It was shown that quercetin has the ability to chelate zinc ions and act as zinc ionophore. Therefore, quercetin could have antiviral activity against many RNA viruses . Quercetin, a flavonoid found in fruits and vegetables, has unique biological properties that may improve mental/physical performance and reduce infection risk ; These properties form the basis for potential benefits to overall health and disease resistance, including anti-carcinogenic, anti-inflammatory, antiviral, antioxidant, and psychostimulant activities, as well as the ability to inhibit lipid peroxidation, platelet aggregation and capillary permeability, and to stimulate mitochondrial biogenesis .There are various studies that report the immunomodulatory effect of bromelain . Bromelain activates natural killer cells and augments the production of granulocyte-macrophage-colony stimulating factor, IL-2, IL-6 and decreases the activation of Thelper cells. Thus, bromelain decreases the majority of inflammatory mediators and has demonstrated a significant role as an anti-inflammatory agent in various conditions Vitamin C is known as an essential anti-oxidant.,and enzymatic co-factor for physiological reactions such as hormone production, collagen synthesis and immune potentiation . Naturally, an insufficiency of vitamin C leads to severe injuries to multiple organs, especially to the heart and brain, since they are both highly aerobic organs that produce more oxygen radicals. In fact, studies of in vivo effect on vitamin C are difficult since most animals, except human and some primate, are capable of synthesizing vitamin C endogenously

NCT04468139

Conditions

1. Covid-19

Interventions

1. Drug: Quercetin
2. Dietary Supplement: bromelain
3. Drug: Zinc
4. Drug: Vitamin C

To measure the effect of Ivermectin (sub-cutaneous) with or without zinc and Nigella sativa in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.

NCT04472585

Conditions

1. Coronavirus Infection
2. COVID
3. Sars-CoV2

Interventions

1. Drug: Nigella Sativa / Black Cumin
2. Drug: Ivermectin Injectable Solution
3. Other: Placebo
4. Drug: Zinc

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.

NCT04482686

Conditions

1. COVID
2. Covid-19
3. Corona Virus Infection
4. Coronavirus Infection
5. Coronavirus-19
6. SARS-CoV2
7. SARS-CoV Infection

Interventions

1. Drug: Ivermectin
2. Drug: Doxycycline Hcl
3. Dietary Supplement: Zinc
4. Dietary Supplement: Vitamin D3
5. Dietary Supplement: Vitamin C

MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

Evaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19 Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized Comparative Study

NCT04528927

Conditions

1. COVID 19
2. Patients Hospitalized

Interventions

1. Drug: HCQ
2. Drug: Azithromycin
3. Drug: Doxycycline
4. Dietary Supplement: Zinc

MeSH:Respiratory Insufficiency